Xenetic Biosciences (XBIO) Fundamental Analysis: Revenue, Earnings & Valuation

4.45 / 10

Netural

The stock's fundamentals show balanced quality (4.5/10). Favorable features: Interest coverage ratio (EBIT / Interest expense) (%) and PB-ROE, balanced by issues in Asset-MV and Fixed assets turnover ratio. Analytical stance: constrained.

Analysis Checks(8/10)

Revenue-MV

Value-0.39

Score3/3

Weight50.70%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value19.04

Score2/3

Weight2.04%

1M Return0.41%

Inventory turnover ratio

Value98.02

Score2/3

Weight-5.31%

1M Return-1.19%

Profit-MV

Value0.62

Score2/3

Weight22.13%

1M Return4.10%

PB-ROE

Value-0.66

Score2/3

Weight24.41%

1M Return4.39%

Fixed assets turnover ratio

Value8528.00

Score1/3

Weight-7.69%

1M Return-1.72%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-4.93%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value19.04

Score2/3

Weight3.40%

1M Return0.68%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight-6.18%

1M Return-1.40%

Asset-MV

Value-0.72

Score1/3

Weight21.44%

1M Return3.90%

Is XBIO undervalued or overvalued?

XBIO scores 4.45/10 on fundamentals and holds a Fair valuation at present. Backed by its -40.00% ROE, -90.07% net margin, -2.69 P/E ratio, 0.98 P/B ratio, and 38.52% earnings growth, these metrics solidify its Netural investment rating.